Efficacy and safety of GLP-1 receptor agonists or GIP/GLP-1 receptor agonists in patients with diabetes ~ Multicenter retrospective cohort study

Efficacy and safety of GLP-1 receptor agonists or GIP/GLP-1 receptor agonists in patients with diabetes ~ Multicenter retrospective cohort study - Study on the efficacy and safety of GLP-1 receptor agonists or GIP/GLP-1 receptor agonists in patients with diabetes

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056556

Enrollment

200

Registered

2024-12-24

Start date

2024-07-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 18 years or older who received a new GLP-1 receptor agonist (Liraglutide, exenatide, lixisenatide, dulaglutide, semaglutide) or GIP/GLP-1 receptor agonist (tilzepatide) during the observation period. Gender includes both men and women.

Exclusion criteria

Exclusion criteria: 1. Patients with advanced-stage malignancies at the time of introduction of GLP-1 receptor agonists or GIP/GLP-1 receptor agonists. 2. Patients with active infection at the time of introduction of GLP-1 or GIP/GLP-1 receptor agonists. 3. Patients with reduced ADL at the time of introduction of GLP-1 or GIP/GLP-1 receptor agonists. 4. Patients with inadequate data from 4 weeks before initiation of GLP-1 receptor agonists or GIP/GLP-1 receptor agonists to 24 weeks after initiation. 5. Patients in whom another antidiabetic drug was added within 3 months prior to the observation period. 6. Other subjects judged by the research director to be inappropriate as research subjects. 7. Those who have expressed their intention to refuse participation by opting out.

Design outcomes

Primary

Measure	Time frame
Changes in HbA1c and body weight before and after initiation of GLP-1 receptor agonists or GIP/GLP-1 receptor agonists	—

Countries

Japan

Contacts

Public ContactHiroaki Ueno

Faculty of Internal Medicine, University of Miyazaki Division of Hematology, Diabetes, and Endocrinology,Department of Internal Medicine

intron@med.miyazaki-u.ac.jp+81-985-85-9121

Outcome results